期刊
CANCER RESEARCH
卷 73, 期 11, 页码 3470-3480出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-4524-T
关键词
-
类别
资金
- AstraZeneca
- Celgene
- CeMines
- Exelixis/Sanofi
- GSK
- Roche
- Wyeth/Pfizer/Puma
- Cancer Center Support Grant (CCSG) [1CA16672]
- Susan G. Komen Promise grant [KG081694]
- Komen SAB grant [9SAB12-00006]
Triple-negative breast cancers (TNBC) are aggressive with no effective targeted therapies. A combined database analysis identified 32 inflammation-related genes differentially expressed in TNBCs and 10 proved critical for anchorage-independent growth. In TNBC cells, an LPA-LPAR2-EZH2 NF-kappa B signaling cascade was essential for expression of interleukin (IL)-6, IL-8, and CXCL1. Concurrent inhibition of IL-6 and IL-8 expression dramatically inhibited colony formation and cell survival in vitro and stanched tumor engraftment and growth in vivo. A Cox multivariable analysis of patient specimens revealed that IL-6 and IL-8 expression predicted patient survival times. Together these findings offer a rationale for dual inhibition of IL-6/IL-8 signaling as a therapeutic strategy to improve outcomes for patients with TNBCs. (C) 2013 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据